Intracranial B7-H3 CAR-T Shows Early Promise in Recurrent Glioblastoma
A first-in-human phase 1 trial of locoregional TX103 CAR-T establishes tolerability and a recommended dose for recurrent glioblastoma, though efficacy signals remain preliminary and relevant chiefly to neuro-oncology pharmacy practice within clinical trial settings.
CAR-T cell therapy offers new hope for recurrent glioblastoma.
Recurrent glioblastoma has limited treatments, and this trial explores a novel option with CAR-T cells targeting B7-H3. TX103 was well tolerated without dose-limiting toxicities; 12-month survival rate was 66.7% with a median overall survival of 19.1 months. This study indicates potential for TX103 to be a viable therapy for recurrent glioblastoma, though larger trials are necessary to confirm efficacy. Intracranial delivery of B7-H3-targeting CAR-T cells shows promise in recurrent glioblastoma therapy.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Zhang Y, Chi X, Feng R, Xian N, Huang N, Sun S, Zhao X, Zhang P, Liu K, Ma Y, Zhang Y, Zhang K, Wang S, Chen X, Zhang J, Huang W, Huang B, Su TT, Yeung J, He J, Chen L, Ji N, Huang G
Citation:Zhang Y, Chi X, Feng R, et al. Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial. Nature medicine. 2026. doi:10.1038/s41591-026-04557-6
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.